Evidence map›Paper›PMID 42074325›Full record

ArticleInternational journal of molecular sciences2026

miR-136-5p Preferentially Suppresses Cancer Stem-like Cells in Pancreatic Cancer.

Hiroyuki Yamamoto, Yuhki Yokoyama, Shihori Kouda, Ruijia Yang, Yingjue Zhang, Jiaqi Wang, Yoshihiro Morimoto, Tsuyoshi Hata, Akira Inoue, Daisuke Okuzaki and 5 more

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Hiroyuki YamamotoDepartment of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, The University of Osaka, Suita 565-0871, Japan.
Yuhki YokoyamaDepartment of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, The University of Osaka, Suita 565-0871, Japan.
Shihori KoudaDepartment of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, The University of Osaka, Suita 565-0871, Japan.
Ruijia YangDepartment of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, The University of Osaka, Suita 565-0871, Japan.
Yingjue ZhangDepartment of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, The University of Osaka, Suita 565-0871, Japan.
Jiaqi WangDepartment of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, The University of Osaka, Suita 565-0871, Japan.
Yoshihiro MorimotoDepartment of Surgery, Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita 565-0871, Japan.ORCID 0000-0003-2687-9933
Tsuyoshi HataDepartment of Surgery, Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita 565-0871, Japan.
Akira InoueDepartment of Gastroenterological Surgery, Ikeda City Hospital, Ikeda 563-8510, Japan.
Daisuke OkuzakiLaboratory for Human Immunology (Single Cell Genomics), WPI Immunology Frontier Research Center, The University of Osaka, Suita 565-0871, Japan.ORCID 0000-0002-4552-783X
Naotsugu HaraguchiDepartment of Gastroenterological Surgery, Kindai University Nara Hospital, Ikoma 630-0293, Japan.
Hidekazu TakahashiDepartment of Gastroenterological Surgery, Osaka International Medical and Science Center, Osaka Keisatsu Hospital, Osaka 543-0042, Japan.
Satoshi ShibataDepartment of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, The University of Osaka, Suita 565-0871, Japan.
Hirofumi YamamotoDepartment of Molecular Pathology, Division of Health Sciences, Graduate School of Medicine, The University of Osaka, Suita 565-0871, Japan.ORCID 0000-0001-6959-9574
Masaki MoriGraduate School of Medicine, Tokai University, Isehara 259-1193, Japan.

Funding

Japan Society for the Promotion of Science 15H04920Japan Society for the Promotion of Science 24H00642
6 · The paper itself

Abstract

In pancreatic cancer, cancer stem-like cells (CSCs) contribute to tumor initiation, reduced drug sensitivity, and recurrence. Limited strategies are currently available to target this cell population. Here we used a proteasome-low CSC enrichment system to identify microRNAs that negatively regulate CSC-like properties. From PANC-1 cells expressing a ZsGreen-ODC degron reporter, a proteasome-low population was isolated through sequential fluorescence-activated cell sorting of ZsGreen-positive cells. Molecular and functional analyses confirmed the CSC-like phenotype of this cell population. Integrated in silico analysis was used to select 31 microRNAs predicted to target CSC-related molecules, which were then evaluated by in vitro viability-based screening to identify candidates that selectively suppressed the viability of CSC-like cells, relative to non-CSCs. Moreover, comprehensive miRNA expression profiling revealed that miR-136-5p was downregulated in the CSC-like population and was therefore selected for further analysis. Mechanistically, miR-136-5p directly targets the 3' untranslated region of DCLK1 and reduces its expression, with a greater reduction in the short isoform. Finally, in a CSC-derived xenograft mouse model, systemic delivery of miR-136-5p using super carbonate apatite nanoparticles significantly suppressed tumor growth. Taken together, these findings suggest that miR-136-5p restoration may provide a therapeutic approach for targeting CSC-driven tumor growth in pancreatic cancer.

Indexed as

MicroRNAsNeoplastic Stem CellsPancreatic Neoplasms3' Untranslated RegionsAnimalsCell Line, TumorDoublecortin-Like KinasesGene Expression Regulation, NeoplasticHumansIntracellular Signaling Peptides and ProteinsMiceMice, NudeProtein Serine-Threonine KinasesXenograft Model Antitumor Assays3' Untranslated RegionsDCLK1 protein, humanDoublecortin-Like KinasesIntracellular Signaling Peptides and ProteinsMicroRNAsMIRN136 microRNA, humanProtein Serine-Threonine Kinasescancer stem-like cellsDCLK1drug sensitivitymiR-136-5pmiRNA-based therapypancreatic cancer

Identifiers

PMID42074325
PMCPMC13116679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.